Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 May;40(5):1180–1185. doi: 10.1128/aac.40.5.1180

Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro.

G Civitico 1, T Shaw 1, S Locarnini 1
PMCID: PMC163287  PMID: 8723462

Abstract

Safe and effective treatments for chronic hepatitis B virus (HBV) infection have yet to be developed. Both ganciclovir (9-[1,3-dihydroxy-2-propoxymethyl]guanine) and foscarnet (trisodium phosphonoformate hexahydrate) are potent inhibitors of hepadnavirus replication when used individually in vitro and in vivo. However, the clinical usefulness of each drug is reduced by dose-limiting toxicity, especially during long-term monotherapy. Here we demonstrate additive inhibition of duck HBV DNA replication in cultures of primary duck hepatocytes congenitally infected with duck HBV by combinations of ganciclovir and foscarnet at low, clinically achievable concentrations. These results suggest that the effects of ganciclovir and foscarnet against HBV may be additive in vivo.

Full Text

The Full Text of this article is available as a PDF (307.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angus P., Richards M., Bowden S., Ireton J., Sinclair R., Jones R., Locarnini S. Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection. J Gastroenterol Hepatol. 1993 Jul-Aug;8(4):353–357. doi: 10.1111/j.1440-1746.1993.tb01527.x. [DOI] [PubMed] [Google Scholar]
  2. Bain V. G., Daniels H. M., Chanas A., Alexander G. J., Williams R. Foscarnet therapy in chronic hepatitis B virus E antigen carriers. J Med Virol. 1989 Oct;29(2):152–155. doi: 10.1002/jmv.1890290214. [DOI] [PubMed] [Google Scholar]
  3. Belen'kii M. S., Schinazi R. F. Multiple drug effect analysis with confidence interval. Antiviral Res. 1994 Sep;25(1):1–11. doi: 10.1016/0166-3542(94)90089-2. [DOI] [PubMed] [Google Scholar]
  4. Bishop N., Civitico G., Wang Y. Y., Guo K. J., Birch C., Gust I., Locarnini S. Antiviral strategies in chronic hepatitis B virus infection: I. Establishment of an in vitro system using the duck hepatitis B virus model. J Med Virol. 1990 Jun;31(2):82–89. doi: 10.1002/jmv.1890310204. [DOI] [PubMed] [Google Scholar]
  5. Civitico G. M., Locarnini S. A. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. Virology. 1994 Aug 15;203(1):81–89. doi: 10.1006/viro.1994.1457. [DOI] [PubMed] [Google Scholar]
  6. Civitico G., Wang Y. Y., Luscombe C., Bishop N., Tachedjian G., Gust I., Locarnini S. Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds. J Med Virol. 1990 Jun;31(2):90–97. doi: 10.1002/jmv.1890310205. [DOI] [PubMed] [Google Scholar]
  7. Crumpacker C. S., Kowalsky P. N., Oliver S. A., Schnipper L. E., Field A. K. Resistance of herpes simplex virus to 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine: physical mapping of drug synergism within the viral DNA polymerase locus. Proc Natl Acad Sci U S A. 1984 Mar;81(5):1556–1560. doi: 10.1073/pnas.81.5.1556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dean J., Bowden S., Locarnini S. Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir. Antiviral Res. 1995 May;27(1-2):171–178. doi: 10.1016/0166-3542(94)00081-i. [DOI] [PubMed] [Google Scholar]
  9. Dieterich D. T., Poles M. A., Lew E. A., Mendez P. E., Murphy R., Addessi A., Holbrook J. T., Naughton K., Friedberg D. N. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J Infect Dis. 1993 May;167(5):1184–1188. doi: 10.1093/infdis/167.5.1184. [DOI] [PubMed] [Google Scholar]
  10. Fautz R., Husein B., Hechenberger C. Application of the neutral red assay (NR assay) to monolayer cultures of primary hepatocytes: rapid colorimetric viability determination for the unscheduled DNA synthesis test (UDS). Mutat Res. 1991 Oct;253(2):173–179. doi: 10.1016/0165-1161(91)90130-z. [DOI] [PubMed] [Google Scholar]
  11. Fourel I., Hantz O., Cova L., Allaudeen H. S., Trepo C. Main properties of duck hepatitis B virus DNA polymerase: comparison with the human and woodchuck hepatitis B virus DNA polymerases. Antiviral Res. 1987 Nov;8(4):189–199. doi: 10.1016/0166-3542(87)90073-8. [DOI] [PubMed] [Google Scholar]
  12. Frank K. B., Cheng Y. C. Mutually exclusive inhibition of herpesvirus DNA polymerase by aphidicolin, phosphonoformate, and acyclic nucleoside triphosphates. Antimicrob Agents Chemother. 1985 Apr;27(4):445–448. doi: 10.1128/aac.27.4.445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Freitas V. R., Fraser-Smith E. B., Matthews T. R. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Antiviral Res. 1989 Nov;12(4):205–212. doi: 10.1016/0166-3542(89)90030-2. [DOI] [PubMed] [Google Scholar]
  14. Ilsley D. D., Lee S. H., Miller W. H., Kuchta R. D. Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action. Biochemistry. 1995 Feb 28;34(8):2504–2510. doi: 10.1021/bi00008a014. [DOI] [PubMed] [Google Scholar]
  15. Jilbert A. R., Freiman J. S., Gowans E. J., Holmes M., Cossart Y. E., Burrell C. J. Duck hepatitis B virus DNA in liver, spleen, and pancreas: analysis by in situ and Southern blot hybridization. Virology. 1987 Jun;158(2):330–338. doi: 10.1016/0042-6822(87)90205-4. [DOI] [PubMed] [Google Scholar]
  16. Lin E., Luscombe C., Wang Y. Y., Shaw T., Locarnini S. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 1996 Feb;40(2):413–418. doi: 10.1128/aac.40.2.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Locarnini S. Design of new anti-viral agents for chronic hepatitis B virus infection. J Gastroenterol Hepatol. 1991;6 (Suppl 1):18–22. doi: 10.1111/j.1440-1746.1991.tb01161.x. [DOI] [PubMed] [Google Scholar]
  18. Locarnini S., Guo K., Lucas R., Gust I. Inhibition of HBV DNA replication by ganciclovir in patients with AIDS. Lancet. 1989 Nov 18;2(8673):1225–1226. doi: 10.1016/s0140-6736(89)91839-4. [DOI] [PubMed] [Google Scholar]
  19. Luscombe C., Pedersen J., Bowden S., Locarnini S. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy. Liver. 1994 Aug;14(4):182–192. doi: 10.1111/j.1600-0676.1994.tb00072.x. [DOI] [PubMed] [Google Scholar]
  20. Löfgren B., Nordenfelt E., Oberg B. Inhibition of RNA- and DNA-dependent duck hepatitis B virus DNA polymerase activity by nucleoside and pyrophosphate analogs. Antiviral Res. 1989 Dec;12(5-6):301–310. doi: 10.1016/0166-3542(89)90057-0. [DOI] [PubMed] [Google Scholar]
  21. Manischewitz J. F., Quinnan G. V., Jr, Lane H. C., Wittek A. E. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1990 Feb;34(2):373–375. doi: 10.1128/aac.34.2.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Marion P. L. Development of antiviral therapy for chronic infection with hepatitis B virus. Curr Top Microbiol Immunol. 1991;168:167–183. doi: 10.1007/978-3-642-76015-0_8. [DOI] [PubMed] [Google Scholar]
  23. McMillan J. S., Shaw T., Angus P. W., Locarnini S. A. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology. 1995 Jul;22(1):36–43. [PubMed] [Google Scholar]
  24. Miller R. H., Robinson W. S. Hepatitis B virus DNA forms in nuclear and cytoplasmic fractions of infected human liver. Virology. 1984 Sep;137(2):390–399. doi: 10.1016/0042-6822(84)90231-9. [DOI] [PubMed] [Google Scholar]
  25. Niu J., Wang Y., Dixon R., Bowden S., Qiao M., Einck L., Locarnini S. The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus. Antiviral Res. 1993 Jun;21(2):155–171. doi: 10.1016/0166-3542(93)90051-j. [DOI] [PubMed] [Google Scholar]
  26. Offensperger W. B., Walter E., Offensperger S., Zeschnigk C., Blum H. E., Gerok W. Duck hepatitis B virus: DNA polymerase and reverse transcriptase activities of replicative complexes isolated from liver and their inhibition in vitro. Virology. 1988 May;164(1):48–54. doi: 10.1016/0042-6822(88)90618-6. [DOI] [PubMed] [Google Scholar]
  27. Prichard M. N., Shipman C., Jr A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 1990 Oct-Nov;14(4-5):181–205. doi: 10.1016/0166-3542(90)90001-n. [DOI] [PubMed] [Google Scholar]
  28. Seeger C., Summers J., Mason W. S. Viral DNA synthesis. Curr Top Microbiol Immunol. 1991;168:41–60. doi: 10.1007/978-3-642-76015-0_3. [DOI] [PubMed] [Google Scholar]
  29. Shaw T., Amor P., Civitico G., Boyd M., Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother. 1994 Apr;38(4):719–723. doi: 10.1128/aac.38.4.719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Shaw T., Locarnini S. A. Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Liver. 1995 Aug;15(4):169–184. doi: 10.1111/j.1600-0676.1995.tb00667.x. [DOI] [PubMed] [Google Scholar]
  31. Sherker A. H., Hirota K., Omata M., Okuda K. Foscarnet decreases serum and liver duck hepatitis B virus DNA in chronically infected ducks. Gastroenterology. 1986 Oct;91(4):818–824. doi: 10.1016/0016-5085(86)90681-5. [DOI] [PubMed] [Google Scholar]
  32. Staschke K. A., Colacino J. M. Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5'-triphosphate of fialuridine. J Virol. 1994 Dec;68(12):8265–8269. doi: 10.1128/jvi.68.12.8265-8269.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Summers J., Mason W. S. Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate. Cell. 1982 Jun;29(2):403–415. doi: 10.1016/0092-8674(82)90157-x. [DOI] [PubMed] [Google Scholar]
  34. Sühnel J. Evaluation of synergism or antagonism for the combined action of antiviral agents. Antiviral Res. 1990 Jan;13(1):23–39. doi: 10.1016/0166-3542(90)90042-6. [DOI] [PubMed] [Google Scholar]
  35. Tuttleman J. S., Pugh J. C., Summers J. W. In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus. J Virol. 1986 Apr;58(1):17–25. doi: 10.1128/jvi.58.1.17-25.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Wang G. H., Seeger C. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell. 1992 Nov 13;71(4):663–670. doi: 10.1016/0092-8674(92)90599-8. [DOI] [PubMed] [Google Scholar]
  37. Wang Y., Luscombe C., Bowden S., Shaw T., Locarnini S. Inhibition of duck hepatitis B virus DNA replication by antiviral chemotherapy with ganciclovir-nalidixic acid. Antimicrob Agents Chemother. 1995 Feb;39(2):556–558. doi: 10.1128/aac.39.2.556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Yokota T., Konno K., Chonan E., Mochizuki S., Kojima K., Shigeta S., de Clercq E. Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro. Antimicrob Agents Chemother. 1990 Jul;34(7):1326–1330. doi: 10.1128/aac.34.7.1326. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES